The ADRD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADRD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ADRD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ADRD Detailed Price Forecast - CNN Money||View ADRD Detailed Summary - Google Finance|
|View ADRD Detailed Summary - Yahoo! Finance||View ADRD Stock Research & Analysis - Zacks.com|
|View ADRD Trends & Analysis - Trade-Ideas||View ADRD Major Holders - Barrons|
|View ADRD Call Transcripts - NASDAQ||View ADRD Breaking News & Analysis - Seeking Alpha|
|View ADRD Annual Report - CompanySpotlight.com||View ADRD OTC Short Report - OTCShortReport.com|
|View ADRD Fundamentals - TradeKing||View ADRD SEC Filings - Bar Chart|
|View Historical Prices for ADRD - The WSJ||View Performance/Total Return for ADRD - Morningstar|
|View the Analyst Estimates for ADRD - MarketWatch||View the Earnings History for ADRD - CNBC|
|View the ADRD Earnings - StockMarketWatch||View ADRD Buy or Sell Recommendations - MacroAxis|
|View the ADRD Bullish Patterns - American Bulls||View ADRD Short Pain Metrics - ShortPainBot.com|
|View ADRD Stock Mentions - StockTwits||View ADRD Stock Mentions - PennyStockTweets|
|View ADRD Stock Mentions - Twitter||View ADRD Investment Forum News - Investor Hub|
|View ADRD Stock Mentions - Yahoo! Message Board||View ADRD Stock Mentions - Seeking Alpha|
|View Insider Transactions for ADRD - SECform4.com||View Insider Transactions for ADRD - Insider Cow|
|View ADRD Major Holdings Summary - CNBC||View Insider Disclosure for ADRD - OTC Markets|
|View Insider Transactions for ADRD - Yahoo! Finance||View Institutional Holdings for ADRD - NASDAQ|
|View ADRD Stock Insight & Charts - FinViz.com||View ADRD Investment Charts - StockCharts.com|
|View ADRD Stock Overview & Charts - BarChart||View ADRD User Generated Charts - Trading View|
What Analysts Recommend for AstraZeneca in March 2018
Posted on Wednesday March 14, 2018
As discussed earlier, AstraZeneca surpassed Wall Street analyst estimates for earnings per share (or EPS) and revenues and reported EPS of $1.03 on revenues of ~$5.8 billion in 4Q17, a 3% increase in revenues as compared to revenues of 4Q16. AstraZeneca’s stock price has increased by nearly 14.9% over the last 12 months but decreased by ~2.6% in 2018 year-to-date. Wall Street analysts have a 12-month target price of $39.09 per share as compared to the last price of $33.78 per share as of March 8, 2018.
Sanofi’s Established Prescription Products in 4Q17
Posted on Friday March 02, 2018
Must-Read Notes on Sanofi's 4Q17 Earnings
Ablynx Acquisition Strengthens SNY’s Rare Blood Disorder Platform
Posted on Friday February 09, 2018
Ablynx (ABLX) is a Belgium-based biopharmaceutical company engaged in the development and commercialization of nanobodies. Ablynx currently has more than 45 proprietary and partnered programs for the development of new treatments in the therapeutic areas of hematology, inflammation, respiratory disease, oncology, and immuno-oncology. The company has existing collaborations with a number of pharma giants, including Novartis (NVS), Merck & Co. (MRK), and AbbVie (ABBV). Ablynx is listed on Euronext Brussels and the NASDAQ.
Sanofi’s $11.6 Billion Bioverativ Acquisition: Highlights
Posted on Wednesday February 07, 2018
On January 22, 2018, Sanofi (SNY) announced that it had entered into an agreement with Bioverativ (BIVV) to acquire all of its outstanding shares for $105 per share in cash. The acquisition price of $105 per share represented a premium of 64% to Bioverativ stock’s closing price on January 19, 2018. The boards of directors of Sanofi and Bioverativ unanimously approved the acquisition.